Sun Pharmaceutical Industries share news, announcements and annual reports
NSE: SUNPHARMABSE: 524715Pharmaceuticals & BiotechnologyLarge Cap
Sun Pharmaceutical Industries Limited · Formerly Sun Pharmaceuticals Industries · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Dec 1994 on BSE, Feb 1995 on NSE
Last close ₹1,777.70up ₹16.70 (0.95%)BSE ₹1,778.25
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,761.00.
30 Oct: open ₹1,769.00, high ₹1,855.00, low ₹1,766.20
52-week range of traded prices to 30 Oct 2026
₹1,583.70Low, 29 Jan 2026₹2,046.90High, 31 Jul 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹4,26,530 Cr13th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 38.90
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,962 crore of one-off items, the largest of them in the quarter to Sep 2026.
- 32.99
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.78
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.90%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 13.1%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,962 crore of one-off items, the largest of them in the quarter to Sep 2026.
- 15.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 16.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.03
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 51,30,21833.2% delivered
Sun Pharmaceutical Industries board meetings
110 filed, newest first. Page 2 of 3.
Aug 2017
11 Aug · Board meeting
Jul 2017
May 2017
26 May · Board meeting
26 May · Board meeting
Feb 2017
14 Feb · Board meeting
Jan 2017
Nov 2016
11 Nov · Board meeting
10 Nov · Board meeting
Oct 2016
Aug 2016
May 2016
30 May · Board meeting
30 May · Board meeting
Jan 2016
Oct 2015
Aug 2015
Jul 2015
May 2015
30 May · Board meeting
Audited results are subject to revision so as to give effect to the amalgamation of Sun Pharma Global Inc, Company's wholly owned subsidiary company, with the Company with effect from January 1, 2015, after receipt of all required approvals from the statutory authorities in respect of the said Scheme of Amalgamation. Please further note that the decision about the recommendation of dividend for the year under review would be made at the time of approving final accounts after giving effect to the above referred Scheme of Amalgamation.
Jan 2015
30 Jan · Board meeting
Inter alia, to consider and take on record the Unaudited Financial Results of the Company for the third quarter and nine months ended December 31, 2014.
Oct 2014
29 Oct · Board meeting
Inter alia, to consider and take on record the un-audited financial results of the Company for the second quarter ended September 30, 2014.
Aug 2014
13 Aug · Board meeting
Board of Directors of the Company at its meeting held on August 12, 2014 has recorded approval of Scheme of Arrangement & Reconstruction between Sun Pharmaceutical Industries Ltd., and Sun Pharma Global FZE in the nature of demerger and transfer of the Specified Undertaking of Sun Pharma Global FZE to the Company with effect from the appointed date of May 01, 2013 as per the order of the Hon'ble High Court of Gujarat, at Ahmedabad at Its hearing held on July 10, 2014 and accordingly after taking into effect of the above Scheme, approved the revised annual accounts for the year ended March 31, 2014.
Jul 2014
30 Jul · Board meeting
Board of Directors of the Company would meet on August 12, 2014 to transact, inter alia, the following business. (i) Consider the revised audited annual accounts of the Company for the year ended March 31, 2014 after giving the effect to the above mentioned Scheme of Arrangement and Reconstruction between SPIL and SPGFZE. (ii) To consider the recommendation of payment of dividend on equity shares for the year ended March 31, 2014 subject to the approval of the shareholders at the ensuing Annual General Meeting. (iii) To consider and take on record the un-audited financial results of the Company for the first quarter ended June 30, 2014 (Q1). The window closure for Trading by Designated persons as per Insider Trading Rules of the Company will be from August 01, 2014 to August 14, 2014 (both days inclusive).
May 2014
29 May · Board meeting
Apr 2014
Jan 2014
27 Jan · Board meeting
Interalia, to consider and take on record the un-audited financial results of the Company for the third quarter ended December 31, 2013.
Oct 2013
28 Oct · Board meeting
Interalia, to consider and take on record the un-audited financial results of the Company for the second quarter / half year ended September 30, 2013.
Jul 2013
24 Jul · Board meeting
Interalia, to consider and take on record the un-audited financial results of the Company for the first quarter ended June 30, 2013
May 2013
14 May · Board meeting
Interalia, (1) To consider and approve the audited financial results of the Company for the year ended March 31, 2013; (2) To consider the recommendation of payment of dividend for the year ended March 31, 2013, subject to the approval of the shareholders at the ensuing Annual General Meeting.
Jan 2013
23 Jan · Board meeting
Inter-alia, to consider and take on record the un-audited financial results of the Company for the third quarter ended December 31, 2012.
Oct 2012
22 Oct · Board meeting
Interalia, to consider and take on record the un-audited financial results of the Company for the second quarter / half year ended September 30, 2012.
Jul 2012
30 Jul · Board meeting
Interalia, to consider and take on record the un-audited financial results of the Company for the first quarter ended June 30, 2012.
May 2012
15 May · Board meeting
Interalia, (1) To consider and approve the audited financial results of the Company for the year ended March 31, 2012; (2) To consider the recommendation of payment of dividend on equity shares for the year ended March 31, 2012, subject to the approval of the shareholders at the ensuing Annual General Meeting.
Feb 2012
2 Feb · Board meeting
Interalia, to consider and take on record the un-audited financial results of the Company for the third quarter/ nine months ended December 31, 2011.
Nov 2011
3 Nov · Board meeting
Interalia, to consider and take on record the un-audited financial results of the Company for the second quarter / half year ended September 30, 2011.
Jul 2011
20 Jul · Board meeting
Interalia, to consider and take on record the un-audited financial results of the Company for the first quarter ended June 30, 2011.
May 2011
14 May · Board meeting
Inter alia (1) To consider and approve the audited financial results of the Company for the year ended March 31, 2011. (2) To consider the recommendation of payment of Dividend on equity shares for the year ended March 31, 2011 subject to the approval of the shareholders at the ensuing Annual General Meeting.
Jan 2011
18 Jan · Board meeting
Interalia, to consider and take on record the un-audited financial results of the Company for the third quarter / nine months ended December 31, 2010.
Oct 2010
18 Oct · Board meeting
Interalia, to consider and take on record the un-audited financial results of the Company for the second quarter / half year ended September 30, 2010.
Jul 2010
13 Jul · Board meeting
Interalia, to consider and take on record the un-audited quarterly financial results of the Company for the first quarter ended June 30, 2010.
May 2010
7 May · Board meeting
Interalia, (1) To consider and approve the audited financial results of the Company for the year ended March 31, 2010. (2) To consider recommendation of payment of dividend on equity shares for the year ended March 31, 2010 subject to the approval of the shareholders at the ensuing Annual General Meeting.
Jan 2010
12 Jan · Board meeting
Meeting on 29 Jan 2010: “Unaudited Financial Results for the qtr ended Dec 31, 2009”
Oct 2009
12 Oct · Board meeting
Meeting on 28 Oct 2009: “Unaudited Financial Results for the Qtr ended Sept 30, 2009”
Jul 2009
14 Jul · Board meeting
Meeting on 29 Jul 2009: “Unaudited Financial Results for the Qtr ended June 30, 2009”
May 2009
19 May · Board meeting
Interalia, (1) To consider the audited financial results of the Company for the year ended March 31, 2009. (2) To consider recommendation of payment of dividend on equity shares for the year ended March 31, 2009 subject to the approval of the shareholders at the ensuing Annual General Meeting.
Jan 2009
16 Jan · Board meeting
Meeting on 30 Jan 2009: “Unaudited Financial Results for the qtr ended Dec 31, 2008”